2271225-13-7
2271225-13-7
Chemical Structure
Rucaparib-d3
Synonym(s): AG014699-d3; PF-01367338-d3
- CAS No.: 2271225-13-7
- Formula:C19H15D3FN3O
- Molecular Weight:326.38
InChIKey: HMABYWSNWIZPAG-FIBGUPNXSA-N
SMILES: O=C1C2=C3C(CCN1)=C(C4=CC=C(C=C4)CNC([2H])([2H])[2H])NC3=CC(F)=C2
Biological Activity: Rucaparib-d3 (AG014699-d3) is the deuterated -labeled Rucaparib (HY-10617A). Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rucaparib-d3 | 98.41% | Rucaparib-d3 (AG014699-d3) is the deuterated -labeled Rucaparib (HY-10617A). Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib (Standard) | 99.89% | Rucaparib (Standard) is the analytical standard of Rucaparib. This product is intended for research and analytical applications. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib-d8 | Rucaparib-d8 (AG014699-d8 ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib | 99.96% | Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib monocamsylate (Standard) | ≥98% | Rucaparib monocamsylate (Standard) is the analytical standard of Rucaparib monocamsylate (HY-102003). This product is intended for research and analytical applications. Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib phosphate | 99.65% | Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib hydrochloride | Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib tartrate | Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rucaparib acetate | Rucaparib (AG014699) acetate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inaxaplin | 99.06% | Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PARP-1-IN-1 | PARP-1-IN-1 is a high selective and orally active PARP-1 inhibitor (IC50=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lerzeparib | Lerzeparib is an (ADP-ribose) polymerase (PARP) inhibitor, with antineoplastic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WD2000-012547 | WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pKi of 8.221. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
